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 Objective To perform a clinicopathological study of patients having renal 
biopsies after liver transplantation.
 Design Case series.
 Setting Queen Mary Hospital, Hong Kong.
 Patients All post–liver transplantation patients who had a renal biopsy in 
the period from January 2000 to December 2010.
 Results Eleven renal biopsies were retrieved for review from 10 patients 
with liver transplantation. The male-to-female ratio was 9:1 (age 
range, 47-63 years). The median liver transplant–to–renal biopsy 
interval was 1590 (range, 102-3699) days. The predominant 
histological changes were interstitial fibrosis and tubular atrophy. 
Diabetic nephropathy (n=6) and immunoglobulin A nephropathy 
(n=4) were the commonest glomerulopathies. Only one patient 
had chronic calcineurin inhibitor nephrotoxicity. With a mean 
follow-up of 53 months, three patients died 2 to 53 months 
post–renal biopsy. All surviving patients had chronic renal 
impairment. Five patients developed end-stage renal failure and 
four had significant persistent proteinuria. 
 Conclusion Renal pathology was variable after liver transplantation; most 
biopsies showed complex renal lesions, whilst calcineurin 
inhibitor nephrotoxicity was rare. The recognition of kidney 
histology attributable to metabolic derangements after liver 
transplantation is potentially important in the interpretation 
of renal biopsy specimens and patient management. The renal 
outlook of this group of patients is guarded.
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Introduction
Renal impairment is a common problem after liver transplantation (LT). The cumulative 
incidence of chronic renal failure after LT is 13.9% and 18.1% over 3 and 5 years, respectively.1 
Studies evaluating renal pathology after LT are sparse and sample sizes are small.2-4 Post-LT 
renal impairment is traditionally attributed to calcineurin inhibitor (CNI), a backbone of 
immunosuppression regimen.1,3,5-7 This view was recently challenged by Kim et al,8 who 
concluded that chronic renal impairment can rarely be ascribed to such toxicity. Many 
investigators have concluded that the cause of renal impairment may be multifactorial, 
complex, and interrelated.2,8-10 Herein, we performed the first local clinicopathological 
analysis of liver transplant recipients who underwent renal biopsy. All the patients were 
recruited from Queen Mary Hospital, The University of Hong Kong, which is the only local 
centre for LT in Hong Kong. 
Methods
Between January 2000 and December 2010, 740 patients received LT (male-to-female 
New knowledge added by this study
• The cause of renal impairment and proteinuria after liver transplantation (LT) in Hong Kong is 
multifactorial and complex.
• Metabolic derangements may account for many of the renal lesions after LT.
Implications for clinical practice or policy
• The outlook of post-LT patients investigated by renal biopsy is associated with significant 
morbidity and mortality.
• Recognition of kidney histology attributable to metabolic derangement after LT has important 
implications for patient management.
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ratio=2.5:1; age range, 1.5 months to 72 years; median 
age, 48 years). Renal biopsy was considered if there 
was proteinuria of >1 g per day and/or significant 
renal impairment (>20% persistent increase in 
serum creatinine from baseline level on at least two 
occasions). Exclusion criteria were known reasons for 
renal impairment (CNI, diabetes mellitus, infections), 
response to modification of immunosuppressives 
 目的 研究肝移植後腎活檢的臨床病理學。
 設計 病例系列。
 安排 香港瑪麗醫院。
 患者 2000年1月至2010年12月期間所有接受肝移植術後進
行腎活檢的病人。
 結果 有10名病人在研究期間接受肝移植並進行共11次腎活
檢。病人年齡介乎47至63歲，男女比例為9:1。從肝
移植到腎活檢的時間差距中位數為1590天（介乎102
至3699天）。主要的病理變化為腎間質纖維化及腎小
管萎縮。最常見的腎小球腎炎是糖尿病腎病（6例）
及免疫球蛋白A型腎病（4例）。只有1個慢性鈣調磷
酸酶抑制劑腎毒性的病例。在53個月的追蹤期內，有
3名病人在腎活檢後的2至53個月內死亡。所有病人均
有慢性腎功能不全。5名病人有終末期腎功能衰竭，
另4名病人有顯著的持續性蛋白尿。
 結論 肝移植後腎活檢的病理學結果有很大差異。大部份活
檢結果都顯示有複雜的腎病變，而慢性鈣調磷酸酶抑
制劑腎毒性的病例卻很少見。肝移植後，代謝紊亂對
於解釋腎穿刺活檢結果和病人管理有潛在價值，亦必
須密切留意這些病人的腎功能。
肝移植後腎活檢的臨床病理學
(lowering CNI dosage, change from a CNI to a 
non-CNI agent), improvement of renal function 
after withdrawal of nephrotoxic agents, serious 
co-morbidity, and no informed consent. During 
the same period, a total of 3398 percutaneous 
renal biopsies were accessed in the Department of 
Pathology, Queen Mary Hospital, The University of 
Hong Kong, of which 12 were from 10 LT patients. 
One renal allograft biopsy (from patient 4, who had 
a combined kidney and pancreas transplantation 65 
months after LT) was excluded from this series. The 
archival materials were jointly reviewed by two renal 
pathologists (co-authors). Patient characteristics, 
biopsy indications, clinical course, and outcomes 
were retrieved from the medical records.
Renal biopsy
All the renal biopsy specimens were routinely 
divided into three portions: the main portion being 
fixed in 10% formalin for paraffin embedding, a small 
portion was fixed in glutaraldehyde for transmission 
electron microscopy, and the rest snap frozen 
for immunofluorescence studies. The paraffin-
embedded tissue was serially sectioned as 3-μm 
thick slices and stained with haematoxylin and eosin, 
periodic acid-Schiff, methenamine silver and Masson’s 
trichrome. Direct immunofluorescence studies were 
carried out on the snap-frozen specimens, using 
FITC-conjugated antisera for immunoglobulin (Ig) 
A, IgG, IgM, C3, C1q and, when indicated, kappa 
and lambda light chains. Ultrastructural examination 
was performed on the glutaraldehyde fixed tissue 
to look for the presence of electron dense deposits, 
and assess the morphology of epithelial cells and any 
abnormalities of the glomerular basement membrane 
(GBM).
* DM denotes diabetes mellitus, HBV hepatitis B virus, HCC hepatocellular carcinoma, HCV hepatitis C virus, HT hypertension, LT liver transplantation, MMF 
mycophenolate mofetil, Y yes, and N no
TABLE 1.  Demographic, clinical, and pathological features of the 10 patients who had renal biopsies after liver transplantation*
Patient 
No.
Sex/age 
(years) 
at renal 
biopsy
Pre-LT 
HT
Pre-LT 
DM
Pre-LT 
dyslipidaemia
Indication of LT Post-LT 
immunosuppression
Post-
LT HT
Post-
LT 
DM
Post-LT 
dyslipidaemia
1 M/62 N Y N HCV cirrhosis; unresectable HCC Steroid/MMF/cyclosporin A Y Y Y
2 M/50 N N N HBV cirrhosis MMF Y Y Y
3 M/55 N N N HBV cirrhosis Steroid Y Y N
4 M/48 N Y N HBV cirrhosis Steroid/tacrolimus Y Y N
5a M/55 N Y N HBV cirrhosis Sirolimus/MMF N Y Y
5b M/63
6 M/47 N N Y HBV cirrhosis and HCV Cyclosporin A/MMF N Y N
7 M/56 N N N HCV cirrhosis Steroid/MMF Y N N
8 M/54 N N N HBV cirrhosis and HCC MMF N N N
9 F/59 Y Y N HBV cirrhosis Tacrolimus Y N Y
10 M/59 N N N HBV cirrhosis Steroid/FK506 Y Y N
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Results
Patient characteristics and outcomes
A total of 11 renal biopsies from 10 patients were 
retrieved; two were from patient 5 and performed 
90 months apart. Metabolic/clinical derangements 
(hypertension, diabetes mellitus, or dyslipidaemia) 
were present pre-transplantation in five patients, and 
developed post-LT in nine. Table 1 summarises the 
demographic, clinical, and pathological features of 
these patients. Their median age was 55 (range, 47-63) 
years, and all but one were male. The indications for 
LT were chronic hepatitis B virus (HBV)–associated 
cirrhosis (n=8). Hepatitis C virus infection was noted 
in three patients, and superimposed hepatocellular 
carcinoma in two. No evidence of rejection was 
documented in any of these patients. 
 The median time elapsing between LT and 
renal biopsy was 1590 (range, 102-3699) days. The 
commonest indication for renal biopsy was significant 
proteinuria (>1 g/24 hour) found in eight patients (in 
7 it was in the nephrotic range). Renal impairment 
was noted in nine patients, seven of whom had both 
significant proteinuria and renal impairment when 
biopsied (Table 2).
 After renal biopsy, immunosuppressive 
therapy was modified in five of the patients.  Such 
modifications included withdrawal of steroid 
(patient 1), change of cyclosporin A to sirolimus 
and prednisolone (patient 6), switching from 
tacrolimus to sirolimus (patient 9), and addition of 
cyclophosphamide (patients 8 and 10). The mean 
follow-up period was 53 (range, 2-119) months 
post–renal biopsy; three patients succumbed at 
2, 48, and 53 months after their renal biopsy. The 
cause of death included gastro-intestinal bleeding 
and post-transplant cerebral lymphoproliferative 
disorder. One patient died outside Hong Kong from 
an unknown cause. End-stage renal failure (ESRF) 
developed in five patients, two of whom underwent 
renal transplantation, including one who had a 
combined kidney and pancreas transplant. All of the 
surviving patients without renal transplantation had 
chronic renal impairment and proteinuria (>1 g/day). 
* CNI denotes calcineurin inhibitor, Cr creatinine, DMN diabetic nephropathy, EBV Epstein Barr virus, ESRF end-stage renal failure, IF/TA interstitial fibrosis/tubular 
atrophy, IgA immunoglobulin A, LT liver transplantation, and MPGN membranoproliferative glomerulonephritis
TABLE 2.  Pathological features and follow-up data of the 10 patients who had renal biopsies after liver transplantation*
Patient 
No.
Indication of renal biopsy Duration after 
LT (days)
Pathology Follow-up
1 Renal impairment: 
Cr 173 µmol/L 
Proteinuria 3.31 g/d
716 DMN; CNI toxicity; arteriolar 
hyalinosis; moderate IF/TA
ESRF requiring haemodialysis 1 year later. Renal 
transplantation at 39 months after biopsy. Now 
normal renal function
2 Renal impairment: 
Cr 157 µmol/L 
Proteinuria 1.92 g/d
2062 DMN; arteriolar hyalinosis; 
moderate IF/TA
Alive with renal impairment: 
Cr 204 µmol/L 
Proteinuria 2.92 g/d
3 Renal impairment : 
Cr 190 µmol/L 
24-Hour proteinuria 7.17 g/L
1590 DMN; arteriolar hyalinosis; 
moderate IF/TA
ESRF on haemodialysis
4 Progressive renal impairment: 
Cr 282 µmol/L 
Proteinuria 14.9 g/d
2496 DMN; arteriolar hyalinosis; 
severe IF/TA
ESRF with combined renal and pancreatic 
transplantation done 13 months later. Now normal 
renal function
5a Nephrotic syndrome: 
Proteinuria 14 g/d
121 IgA nephropathy  -
5b Chronic renal failure: 
Cr up to 1000 µmol/L
2851 DMN; arteriolar hyalinosis; 
severe IF/TA
ESRF on haemodialysis
6 Renal impairment: 
Cr 168 µmol/L 
Proteinuria 6.85 g/d
3699 IgA nephropathy; DMN; arteriolar 
hyalinosis; moderate IF/TA
Chronic renal impairment: 
Cr 230 µmol/L 
Proteinuria 7.47 g/d
7 Proteinuria 4.41 g/d 3072 IgA nephropathy; hypertensive 
nephrosclerosis; arteriolar 
hyalinosis; moderate IF/TA
Chronic renal impairment: 
Cr 207 µmol/L 
Developed EBV-associated post-transplant 
lymphoproliferative disorder in brain and 
subsequently died 53 months after renal biopsy
8 Acute renal impairment: 
Cr 150→492 µmol/L 
Proteinuria 2.4 g/d
176 IgA nephropathy with 50% 
crescents; mild IF/TA
Died in mainland China 2 months later; 
cause unknown
9 Renal impairment: 
Cr 117 µmol/L
102 Hypertensive nephrosclerosis; 
arteriolar hyalinosis; moderate 
IF/TA
Progressive renal impairment: 
Cr 300 µmol/L 
Proteinuria of 1.31 g/d
10 Renal impairment: 
Cr 200→300 µmol/L
866 MPGN; arteriolar hyalinosis; 
severe IF/TA
ESRF and died of gastro-intestinal bleeding 48 
months later
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Renal histopathology
Moderate-to-marked degree of interstitial fibrosis 
and tubular atrophy were common, being present in 
nine biopsies. Arteriolar hyalinosis was also noted in 
the renal biopsies of nine patients, all of whom had 
diabetes mellitus and/or hypertension after LT (Fig 
1a). One patient had nodular hyalinosis involving the 
media and adventitia of renal arterioles, associated 
with myocyte vacuolation and degeneration, in 
which the features were consistent with chronic CNI 
vasculopathy (Fig 1b).
 Regarding the glomerular lesions, six renal 
biopsies showed diabetic glomerulosclerosis; Figure 
1c shows its characteristic features. The glomeruli 
showed increase in mesangial matrix. Characteristic 
exudative lesions with large intracapillary hyaline 
deposits (‘fibrin caps’), which sometimes contain 
lipid, were found. Ultrastructural study revealed 
diffusely thickened basement membranes and 
increase in mesangial matrix. 
 Immune complex (IC) nephritis was evident 
in five biopsies, namely IgA nephropathy (n=4) and 
membranoproliferative glomerulonephritis (MPGN; 
n=1). Figure 1d illustrates the characteristic features 
of IgA nephropathy, there being a variable degree of 
expansion of the mesangial matrix and increase in 
mesangial cellularity. Immunofluorescence studies 
showed heavy deposits of IgA in the mesangium, 
and ultrastructural study confirmed the presence of 
electron dense IC deposits in the mesangium and 
paramesangium. The biopsy of patient 8 revealed 
cellular crescents affecting 50% of the glomeruli. 
In two patients, IgA nephropathy co-existed 
with diabetic glomerulopathy and hypertensive 
nephrosclerosis. The biopsy of the patient with 
MPGN showed typical mesangial interpositioning, 
duplication of the GBM producing double contours, 
and subendothelial IC electron dense deposits (Fig 
1e).
 Patient 5 had LT for liver cirrhosis due to 
chronic HBV infection, and presented with nephrotic 
syndrome and heavy proteinuria (14 g/day) 4 months 
later. Renal biopsy showed IgA nephropathy with 
no significant interstitial fibrosis or tubular atrophy 
(Fig 2a). On ultrastructural study, there were IC-type 
electron dense deposits in the mesangium. The GBM 
was not thickened, therefore diabetic glomerulopathy 
was considered absent. His renal function slowly 
deteriorated with creeping up of the serum creatinine 
level. A repeat renal biopsy 90 months later revealed 
diabetic glomerulopathy (Fig 2b), with no evidence 
FIG 1.  Renal histopathology after liver transplantation 
(a) Significant interstitial fibrosis, tubular atrophy, arterial hyalinosis, and intimal fibrous thickening are common lesions (H&E; original magnification, x 40; 
patient 10). (b) Calcineurin inhibitor nephrotoxicity—the arterioles show marked hyalinosis. Hyaline deposits in the media with nodular appearance (arrows), 
associated with vacuolar degeneration in myocytes, are highly characteristic (PAS; original magnification, x 400; patient 1). (c) Diabetic glomerulopathy—the 
glomerulus shows hyalinosis (exudative) lesions which contain lipid (H&E; original magnification, x 200; patient 2). (d) Immunoglobulin A (IgA) nephropathy—a 
glomerulus shows expansion of mesangial matrix and increase in mesangial cellularity (PAS; original magnification, x 200; patient 7). Immunofluorescence study 
shows strong granular IgA deposits in the mesangium (inset; original magnification, x 200, patient 7). (e) Mesangioproliferative glomerulonephritis—electron 
photomicrograph shows mesangial interpositioning and subendothelial electron dense deposits (original magnification, x 2950; patient 10)
(a)
(d) (e)
(b) (c)
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of IC deposition in immunofluorescence and 
ultrastructural studies. The patient developed ESRF 
after 3 months and started haemodialysis. 
Discussion
The present study involved 11 renal biopsies from 740 
liver transplant patients, giving a rate of 1.5%, which 
was similar to that in other series.4,11 Interstitial fibrosis 
and tubular atrophy were consistently present. Not 
surprisingly, before LT all of our patients suffered 
from cirrhosis that was predominantly due to chronic 
HBV infection. Around 90% of the renal biopsies in 
patients with cirrhosis show chronic tubulointerstitial 
injury,12 and such lesions persist after LT. It is difficult 
to discriminate newly acquired post-transplant 
changes from the wide range of changes described 
as common before LT. For patient 1, the diabetic 
changes evident within 2 years of LT might have 
existed pre-transplant, but appeared to be aggravated 
after the transplant. Thereafter, he had progressive 
disease and developed ESRF. Both IC-mediated 
and non-IC–mediated renal injuries were apparent 
in the patients. Evidently, IC glomerulonephritis 
takes the form of IgA nephropathy and MPGN, and 
both are known to be associated with chronic liver 
disease. The non-immunological lesions included 
arteriolar hyalinosis, diabetic glomerulopathy, and 
hypertensive nephrosclerosis. Most of our renal 
biopsies had more than one pathological lesion, a 
finding also reported by other investigators.4,8-10 
 While many previous studies showed the 
complex, multifactorial nature of renal injuries after 
LT,2,4,8-10 the underlying causes were not explored. 
Although our study was limited by the small number 
of patients, in view of the spectrum of renal lesions 
encountered we believe at least some of them may 
have been related to metabolic derangement after LT. 
Development of post-transplant metabolic syndrome 
(PTMS)—which includes impaired glucose tolerance, 
hypertension, dyslipidaemia, and obesity—has 
become a growing concern.13-15 It was beyond the 
scope of this study to evaluate metabolism before 
and after LT, though PTMS is reported to occur in 43 
to 58% of post-transplant patients and is probably 
related to the effects of immunosuppressive 
drugs.13-15 The return to normal daily life, free food 
intake, and normalisation of the hypermetabolic 
state of advanced liver disease are confounding 
factors.13 The syndrome is believed to increase the 
risk of cardiovascular disease,13-15 and may account 
for conditions such as arteriolar hyalinosis, diabetic 
nephropathy and hypertensive nephrosclerosis, 
which are frequently observed in the biopsies. As five 
patients already had metabolic derangement before 
LT, we believe that aspects of the renal injuries might 
have been sustained earlier. In recent years, achieving 
tolerance to the withdrawal of immunosuppression 
has been a major goal after LT.16,17 An awareness of 
PTMS should alert our transplant surgeons and 
nephrologists on the feasibility of weaning patients 
from immunosuppression. A larger sample size and 
multivariate analysis may clarify the role of PTMS in 
such renal pathology.
 Notably, patient 5 who had IgA nephropathy 
after LT had a repeat renal biopsy 90 months later. This 
revealed diabetic nephropathy as the cause of his ESRF. 
Thus, renal lesions due to metabolic derangements 
can supervene on established IC glomerulonephritis 
as a late cause of renal impairment, and should not 
be ignored/underestimated. This case illustrates the 
pathological heterogeneity and temporal dynamics 
of renal lesions in LT recipients, and reinforces the 
need for constant surveillance. 
 Contrary to the classical concept that in 
LT patients CNI is the probable cause of renal 
FIG 2.  Patient 5 
(a) First renal biopsy shows immunoglobulin A (IgA) nephropathy. 
Mesangial proliferation is apparent in the glomerulus (PAS; 
original magnification, x 100). Immunofluorescence study shows 
mesangial granular IgA deposits (inset; original magnification, x 
200). (b) Renal biopsy repeated 90 months later shows diabetic 
nephropathy. Arteriolar hyalinosis was prominent, involving both 
afferent and efferent arterioles of the glomerulus on the right 
(PAS; original magnification, x 100)
(a)
(b)
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failure,1,3,5-7,11 such nephrotoxicity (nodular hyalinosis 
involving the vessel wall) is a rare feature in biopsies. 
This finding concurs with a recent large study by 
Kim et al,8 who found that only 16% of patients had 
evidence of CNI toxicity in their 81 post-LT renal 
biopsies. Routine monitoring of serum drug levels 
and modification of immunosuppressive therapy 
before renal biopsy could help select patient 
subgroups with a lower risk of CNI toxicity. Sampling 
error was also a possibility, quite apart from the 
somewhat vague diagnostic criteria of ‘chronic 
CNI nephropathy’. Striped interstitial fibrosis, 
arteriolar hyalinosis and glomerular sclerosis—once 
regarded as pathological hallmarks of chronic CNI 
nephrotoxicity—are being challenged and regarded 
as non-specific.18 In view of the frequent presence 
of interstitial fibrosis, arteriolar hyalinosis and 
glomerular sclerosis in post-LT patients, we and Kim 
et al8 only regard nodular hyalinosis of arteries as 
definitively indicative of CNI nephrotoxicity.
 The outlook of LT patients who need to be 
investigated by renal biopsy is not good. After a 
mean follow-up of 53 months post–renal biopsy, 
all the patients had chronic renal impairment, and 
five developed ESRF and three died. Such data were 
comparable to those from western series. In a cohort 
of 26 LT recipients with a mean follow-up of 6 years 
post–renal biopsy, 12 patients were on dialysis and 
all but one suffered from chronic renal failure.9 In a 
1. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure 
after transplantation of a nonrenal organ. N Engl J Med 
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References
similar study of renal biopsies on 81 LT recipients,8 
five died and 11 were on renal replacement treatment 
after a median follow-up of 20 months. Thus, the 
outlook of LT patients having kidney biopsies was 
worse than that of post-LT patients with chronic renal 
failure (~18%)1 and ESRF (<4%).2 The survival of these 
LT patients also compared unfavourably in terms of 
overall long-term drop-out (death and loss to follow-
up) rates of all Hong Kong LT recipients (131/890, 15%).
Conclusion
We report the long-term clinicopathological findings 
of 10 patients having 11 renal biopsies after LT. The 
renal pathological features in the kidneys were 
very often heterogeneous. The most common renal 
lesions included interstitial fibrosis/tubular atrophy, 
arteriolar hyalinosis, diabetic glomerulopathy, 
and IgA nephropathy. On follow-up, there was a 
significant risk of chronic renal failure and mortality. 
Pathologists and nephrologists should attend to the 
renal lesions related to metabolic derangement when 
evaluating renal biopsies in LT patients. 
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